July 21, 2026 07:02 ET | Source: Axiom Biosciences SAN DIEGO, July 21, 2026 (GLOBE NEWSWIRE) — Axiom Biosciences, a clinical-stage biotechnology company whose lead regenerative therapy produced positive early results in newborns with severe brain injury, today announced its intention to pursue an initial public offering on the Main Board of The Stock Exchange of Hong Kong […]
July 20, 2026 11:42 ET | Source: King Faisal Specialist Hospital & Research Centre RIYADH, Saudi Arabia, July 20, 2026 (GLOBE NEWSWIRE) — A father’s decision to give part of his liver to save his son has resulted in a global medical first. King Faisal Specialist Hospital and Research Centre (KFSH) has performed the world’s first liver
July 17, 2026 02:10 ET | Source: Boehringer Ingelheim Not intended for UK and US audiences Ingelheim, Germany – Boehringer Ingelheim today announced that the European Commission (EC) has granted marketing authorization for JASCAYD® (nerandomilast) for the treatment of adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). This marks the first new treatment
July 16, 2026 12:47 ET | Source: Society for Medical Decision Making OSLO, Norway, July 16, 2026 (GLOBE NEWSWIRE) — The Society for Medical Decision Making (SMDM) presented its highest career honor, the 2026 Career Achievement Award, to Professor Uwe Siebert, MPH, MSc, ScD, of UMIT TIROL and Harvard University, recognizing his decades of transformative contributions to medical decision making through groundbreaking research, international
July 16, 2026 03:36 ET | Source: Angelini Pharma ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) — Angelini Pharma S.p.A. (“Angelini Pharma”), international pharmaceutical company and part of Angelini Industries, announces today the completion of its acquisition of Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX). Catalyst is now part of Angelini Pharma, integrating Catalyst’s portfolio and commercial infrastructure with
July 16, 2026 01:00 ET | Source: Boehringer Ingelheim Ingelheim, Germany – Boehringer Ingelheim today announces the start of a Phase II clinical trial evaluating its investigational triple GLP-1/GIP/NPY2 receptor agonist, BI 3034701, in patients with obesity and overweight.1 The trial represents a significant milestone for Boehringer’s cardiometabolic and obesity pipeline, which aims to address obesity as a central
SelSym Biotech joins Persephoni to advance the first shelf-stable, blood-type agnostic hemostatic therapy designed for use at the point of injury, where no such option exists today July 15, 2026 09:00 ET | Source: Persephoni Bio RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) — Persephoni BioSciences (“Persephoni”), a global venture creation platform, today announced that
July 15, 2026 01:36 ET | Source: Boehringer Ingelheim Boehringer Ingelheim reported continued sales growth in the first half of 2026, driven by strong growth in the U.S. due to increased demand for JARDIANCE® (empagliflozin) and successful new launches. Group net sales increased by 16.2%* to EUR 15.8 billion, with Human Pharma contributing EUR 13.1 billion and Animal Health
July 14, 2026 05:00 ET | Source: Hummingbird Bioscience SINGAPORE, July 14, 2026 (GLOBE NEWSWIRE) — Hummingbird Bioscience (“Hummingbird”), a biotherapeutics company discovering and developing transformative medicines for diseases with significant unmet need, today announced that it has won the Asia Pacific Trailblazer Award at the 2026 AI Discovery Awards hosted by Nebius. The AI Discovery Awards by
July 13, 2026 02:30 ET | Source: Alamar Biosciences, Inc. National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences’ NULISAseq™ Neuro 220 panel. Resulting dataset will be publicly accessible, linked through National Alzheimer’s Coordinating Center IDs and open to AI-driven discovery through a national data challenge. Project
Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging July 10, 2026 06:11 ET | Source: Alamar Biosciences, Inc. Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that
Global CRO highlights multi-regional trial delivery, early-phase Australia advantages, and expanding support for biotech sponsors across Asia and China July 09, 2026 19:59 ET | Source: Avance Clinical ADELAIDE, Australia, July 10, 2026 (GLOBE NEWSWIRE) — Avance Clinical, the Australian-headquartered global Contract Research Organization (CRO) for biotechs, today announced its participation in BIO Asia–Taiwan 2026, taking place 15–19
July 09, 2026 08:30 ET | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and ZUG, Switzerland, July 09, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations
July 07, 2026 09:23 ET | Source: Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has started a phased review
July 07, 2026 09:12 ET | Source: Alamar Biosciences, Inc. eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is available in the NULISAseq™ Neuro 220 panel and as a single-plex assay through the Technology Access Program Data to
